850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA

Documenti analoghi

• 230 | TREATMENT OF NEWLY‐DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/‐ NIVOLUMAB‐ INTERIM ANALYSIS OF THE PHASE II TOP‐FLOR STUDY
  di: A. Martynchyck, et al.
  Pubblicazione: (2025)
• 441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
  di: R. Cordoba, et al.
  Pubblicazione: (2025)
• OT04 | GOLSEEK‐1: A PHASE 3, DOUBLE‐BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R‐CHOP VERSUS PLACEBO + R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK, LARGE B‐CELL LYMPHOMA
  di: G. S. Nowakowski, et al.
  Pubblicazione: (2025)
• 148 | GOLCADOMIDE ± RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED PHASE 1/2 RESULTS
  di: E. Bachy, et al.
  Pubblicazione: (2025)
• 231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY
  di: D. Maruyama, et al.
  Pubblicazione: (2025)